Recommended Free Tools
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
CagriSema and tirzepatide act on different hormone targets, and their U.S. regulatory status is not the same. CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue. Tirzepatide activates both GIP and GLP-1 receptors. Both have produced substantial average weight loss in clinical trials, but as of October 4, 2026, tirzepatide is available under FDA-approved brands for specified uses while Novo Nordisk says CagriSema remains under FDA review for weight management.
How the two medicines work
CagriSema combines two hormone-related medicines
CagriSema is Novo Nordisk’s fixed-dose, once-weekly injection of cagrilintide 2.4 mg and semaglutide 2.4 mg. Semaglutide activates GLP-1 receptors; cagrilintide is a long-acting amylin analogue. Novo Nordisk says their combined effect reduces hunger, increases fullness, and helps people eat less and reduce calorie intake.
Tirzepatide activates GIP and GLP-1 receptors
Tirzepatide acts on both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. In the United States, it is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in eligible adults, alongside reduced-calorie eating and increased physical activity. These are brand-specific FDA-approved uses, so check the current prescribing information for the product and indication relevant to you.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11| Comparison | CagriSema | Tirzepatide |
|---|---|---|
| Active medicines or targets | Cagrilintide, a long-acting amylin analogue, plus semaglutide, a GLP-1 receptor agonist | Activates GIP and GLP-1 receptors |
| U.S. status as of October 4, 2026 | Novo Nordisk reported an FDA submission for weight management in December 2025, with a decision anticipated by late 2026; it remained under review on the date stated here. | FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in eligible adults. |
| Evidence discussed here | REDEFINE 1 placebo-controlled trial and Novo Nordisk’s open-label REDEFINE 4 head-to-head report | FDA’s 2023 Zepbound approval announcement and Novo Nordisk’s REDEFINE 4 head-to-head report |
What the weight-loss trials found
CagriSema versus placebo in REDEFINE 1
In the phase 3 REDEFINE 1 trial, adults had obesity or overweight plus at least one weight-related complication and did not have type 2 diabetes. At 68 weeks, estimated mean body-weight change was −20.4% with CagriSema and −3.0% with placebo. The investigators published the result in The New England Journal of Medicine in 2025. These are trial averages from a selected population, not a forecast for an individual.
#1 Best Overall
- 12 MONTH WEIGHT LOSS TRACKER Track your weight loss journey over 12 months with a guided journal designed for recording pounds lost, body measurements, goals and progress.
- POUNDS LOST & BODY MEASUREMENTS Includes 10, 20, 30, 50 and 100 pounds lost trackers, plus body measurement tracking to help you visually follow your progress over time.
- MONTHLY STEP & FITNESS TRACKERS Plan and record movement with monthly step trackers and monthly fitness planner pages, ideal for building consistency around activity and fitness goals.
- VITAMINS, SUPPLEMENTS & REFLECTIONS Includes vitamins and supplements trackers, plus goals and reflections sections to help you stay organised and review your progress throughout the year.
- CHALLENGES TO KEEP YOU MOTIVATED Features 30 day, 12 week and 52 week challenges, giving you different ways to stay focused and create momentum across your weight loss journey.
CagriSema versus tirzepatide in REDEFINE 4
Novo Nordisk reported REDEFINE 4 as an 84-week, open-label trial comparing once-weekly subcutaneous CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg. It randomized 809 people with obesity and at least one comorbidity. The sponsor reported these average weight-loss estimates:
| Analysis approach | CagriSema | Tirzepatide 15 mg |
|---|---|---|
| Estimand assuming adherence, at week 84 (Novo Nordisk, 2026) | 23.0% | 25.5% |
| Treatment-regimen estimand, at week 84 (Novo Nordisk, 2026) | 20.2% | 23.6% |
The adherence estimate asks what weight loss would look like assuming participants adhered to treatment; the treatment-regimen estimate reflects the assigned treatment approach rather than assuming continued adherence. Because REDEFINE 4 was open-label and the figures are sponsor-reported, they are useful direct-comparison evidence but should not be treated as a guarantee for an individual or a complete verdict on which medicine is preferable.
Rank #2
- FOOD JOURNAL FOR HEALTHY - A food journal to tracks daily dietary and nutritional intake for women/men. It will help you stay healthy, get motivated, get rid of bad habits, and achieve your weight loss goals. Focus on your health and eat healthy, this food tracker is all about what you want to improve.
- ACHIEVE GOALS - This fitness and nutrition journal helps you set big goals, break them down into monthly milestones, and work relentlessly toward them. At the end of each month, you will complete a monthly review to reflect your progress.
- UNDATED 6 MONTH MEAL PLANNER - This is a food diary that tracks meals and exercise last for 6 month. Keep daily records of calories, sleep time, water, weight, body fat, and activity. The monthly record can help you pay attention to your health and notice how changing your diet and lifestyle affects how you feel.
- ADDITIONAL - Lovely patterns created by hardcover, high quality of size 5.8" x 8.3", There are 3 sheets colorful stickers to help you plan and stay motivated to continue using this daily journal. What's more, the food journal with 3 ribbon bookmark, elastic band, pen holder and inner pocket for easy use.
- GUARANTEE - If you have any problems with this food journal, please contact us and we will help you solve promptly!
Tirzepatide’s FDA trial context
In its 2023 Zepbound approval announcement, the FDA described two randomized, double-blind, placebo-controlled trials. At 72 weeks, participants receiving the highest approved dose lost an average of 18% of body weight in the trial population without diabetes and 12% in the separate population with type 2 diabetes. Those results came from different trial populations and should not be directly ranked against the REDEFINE 1 CagriSema result.
Free tools Windows power users keep installed
One-click scans. No signup required.
Does one work better for weight loss?
There is no sound way to rank medicines by placing percentages from separate studies side by side without their context. Trial populations, follow-up periods, doses, comparators, analysis methods, and assumptions about treatment adherence can differ. The more relevant direct evidence here is REDEFINE 4, but its open-label design and sponsor-reported estimates matter when interpreting its results.
- Check whether participants had type 2 diabetes; weight-loss trial results can differ by population.
- Compare the same duration and studied dose, not isolated percentages.
- Distinguish placebo-controlled studies from active-comparator studies.
- Note whether an estimate assumes adherence or reflects a treatment-regimen approach.
- Do not assume a trial average predicts your own response; medical history, other medicines, tolerability, and treatment goals affect suitability.
What this means for diabetes treatment
In the United States, tirzepatide has an FDA-approved type 2 diabetes brand, Mounjaro, as well as the weight-management brand Zepbound. CagriSema’s U.S. application described here is for weight management and was still under FDA review as of October 4, 2026. The REDEFINE 1 weight-loss result came from adults without type 2 diabetes, and the evidence summarized here does not establish a like-for-like diabetes-control comparison between CagriSema and tirzepatide.
Weight loss may be relevant to someone managing diabetes, but these trial averages do not establish diabetes remission or predict glucose changes for a particular person. If you have diabetes, discuss treatment goals and glucose monitoring with your clinician, especially if you use insulin or another medicine that can lower blood sugar.
Rank #4
- 150-day/5-month food and fitness journal with measuring tape: this fitness journal allows you to record up to 150 days of fitness and diet data, ensuring you stay on track with your health goals. The measuring tape helps you to track your body dimensions and detailed tracking system helps you monitor progress and make necessary adjustments to your routine
- Structured goal setting and achievement: the 2 goal pages of fitness planner has 10 sections for setting clear objectives, start and end dates, detailed plans, and results. The workout journal also features a reward section to motivate you to achieve your fitness milestones
- Body dimension contrasts by table, photos and chart: the body dimension contrasts can be shown by figures, photos, and progress curves. This visual representation allows you to see tangible changes in your physique over time, providing motivation and a clear sense of achievement
- Integrated calendar and daily tracking: the 2-page undated calendar of weight loss journal provides a monthly overview with daily completion marks and progress curves. The daily tracking pages allow you to log specific exercises, calories burned, and meal calorie intake. This integrated system helps you maintain a consistent routine and stay accountable to your fitness and nutrition goals
- User-friendly design, durable material: the 9.5'' * 7'' fitness journal for women is easy to carry and use, with a waterproof and sweat-proof PP material cover and ink-resistant 100gsm thick paper inside. The elastic band keeps the workout planner closed to keep your data private and organized. Double sided pockets are designed for cards, guidebooks, etc.
Safety points and use with other medicines
The current U.S. Zepbound prescribing information lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, and other reactions among common adverse reactions. It also warns about severe gastrointestinal reactions, gallbladder disease, pancreatitis, kidney injury related to volume depletion, and hypoglycemia when tirzepatide is used with insulin or an insulin secretagogue. People with diabetes should follow the label’s advice on glucose monitoring; it also advises monitoring for progression in people with a history of diabetic retinopathy.
Zepbound carries a boxed warning about thyroid C-cell tumors observed in rats. Its U.S. label contraindicates use for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN2). Discuss your history and current medicines with a clinician rather than using this list as a personal eligibility check.
Best Value
- SMASH YOUR PB'S - Achieve the performance and physique you've always wanted with Nextnoid daily workout journal! Effectively track both daily and weekly workout goals upto 8 months as meticulously as you desire, plan next week's workouts, and celebrate your success with ease. Stay focused!
- GET FITTER, FASTER - Take control of your health and fitness journey and accelerate your results with our fitness planner for women and men! This exercise diary provides you with a proven system to build muscle, improve strength or just be healthier. What gets measured, improves!
- SIMPLE AND CLEAR - Setting yourself up for success has never been easier! Our personal workout book takes the thought and effort out of staying disciplined and accountable with a clear incremental progress system, bigger fonts for easy reading and enough space to jot down everything.
- CAREFULLY CRAFTED - Made with functionality and also long-lasting durability in mind with size 5.7x8.3 in, this fit log journal is tough enough to withstand the rigors of the gym floor, running trail and even the kitchen! Premium thick 120gsm pages and a sweat and tear-proof outer match your grit!
- PERFECT GIFT - Show the fitness enthusiast in your life just how much you care with this workout tracker notebook! Also ideal for the beginner who dreams of being in shape, this fitness training journal could be the motivation they need to kickstart their health and wellness journey!
The FDA says Zepbound should not be combined with Mounjaro or a GLP-1 receptor agonist. Do not treat the brands as separate medicines that can be stacked: Mounjaro and Zepbound contain the same active ingredient, tirzepatide, and their approved uses differ by product label.
Quick Recap
Choosing what to discuss with a clinician
- Which condition is being treated and which product is approved for that use where you live?
- How do your medical history, including any contraindications or past complications, affect suitability?
- Could your other medicines change the risk of low blood sugar or require a monitoring plan?
- What treatment goal matters most, and how will benefit, side effects, and progress be reviewed?
- Which current product label applies? Regulatory status and labeling can change, and statements above about approvals refer to the United States as of October 4, 2026.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
